Klootwijk W, Sleddens-Linkels E, de Boer R, Jansen C A, Autar R, de Herder W W, Boevé E R, Visser T J, de Greef W J
Department of Internal Medicine and Clinical Endocrinology, Erasmus University, Rotterdam, The Netherlands.
J Clin Endocrinol Metab. 1997 Sep;82(9):3068-73. doi: 10.1210/jcem.82.9.4219.
TRH-like peptides have been identified that differ from TRH (pGlu-His-ProNH2) in the middle amino acid. We have estimated TRH-like immunoreactivity (TRH-LI) in human serum and urine by RIA with TRH-specific antiserum 8880 or with antiserum 4319, which binds most peptides with the structure pGlu-X-ProNH2. TRH was undetectable in serum (< 25 pg/mL), but TRH-LI was detected with antiserum 4319 in serum of 27 normal subjects, 21 control patients, and 12 patients with carcinoid tumors (range 17-45, 5-79, and 18-16,600 pg/mL, respectively). Because serum was kept for at least 2 h at room temperature, which causes degradation of TRH, pGlu-Phe-ProNH2, and pGlu-Tyr-ProNH2, serum TRH-LI is not caused by these peptides. On high-performance liquid chromatography, serum TRH-LI coeluted with pGlu-Glu-ProNH2 (< EEP-NH2), a peptide produced in, among others, the prostate. Urine of normals and control patients also contained TRH-LI (range 1.14-4.97 and 0.24-5.51 ng/mL, respectively), with similar levels in males and females. TRH represented only 2% of urinary TRH-LI, and anion-exchange chromatography and high-performance liquid chromatography revealed that most TRH-LI in urine was < EEP-NH2. In patients with carcinoid tumors, increased urinary TRH-LI levels were noted (range 1.35-962.4 ng/mL). Urinary TRH-LI correlated positively with urinary creatinine, and the urinary clearance rate of TRH-LI was similar to the glomerular filtration rate. In addition, serum TRH-LI was increased in 17 hemodialysis patients (43-373 pg/mL). This suggests that serum < EEP-NH2 is cleared by glomerular filtration with little tubular resorption. The possible role of the prostate as a source of urinary TRH-LI was evaluated in 11 men with prostate cancer, showing a 25% decrease in urinary TRH-LI excretion after prostatectomy (0.19 +/- 0.02 vs. 0.15 +/- 0.01 ng/mumol creatinine, mean +/- SEM). However, TRH-LI was similar in spontaneously voided urine and in urine obtained through a nephrostomy cannula from 16 patients with unilateral urinary tract obstruction (0.15 +/- 0.01 vs. 0.14 +/- 0.01 ng/mumol creatinine). These data indicate that: 1) TRH-LI in human serum represents largely < EEP-NH2, which is cleared by renal excretion; 2) part of urinary < EEP-NH2 is derived from prostatic secretion into the blood and not directly into urine; and 3) urinary < EEP-NH2 can be used as marker for carcinoid tumors.
已鉴定出在中间氨基酸上与促甲状腺激素释放激素(TRH,即焦谷氨酸-组氨酸-脯氨酰胺)不同的类TRH肽。我们用TRH特异性抗血清8880或抗血清4319通过放射免疫分析法(RIA)估算了人血清和尿液中的类TRH免疫反应性(TRH-LI),抗血清4319能与大多数具有焦谷氨酸-X-脯氨酰胺结构的肽结合。血清中未检测到TRH(<25 pg/mL),但在27名正常受试者、21名对照患者和12名类癌肿瘤患者的血清中用抗血清4319检测到了TRH-LI(分别为17 - 45、5 - 79和18 - 16,600 pg/mL)。由于血清在室温下保存至少2小时,这会导致TRH、焦谷氨酸-苯丙氨酸-脯氨酰胺和焦谷氨酸-酪氨酸-脯氨酰胺降解,所以血清TRH-LI并非由这些肽引起。在高效液相色谱上,血清TRH-LI与焦谷氨酸-谷氨酸-脯氨酰胺(<EEP-NH2)共洗脱,<EEP-NH2是一种尤其在前列腺中产生的肽。正常人和对照患者的尿液中也含有TRH-LI(分别为1.14 - 4.97和0.24 - 5.51 ng/mL),男性和女性水平相似。TRH仅占尿TRH-LI的2%,阴离子交换色谱和高效液相色谱显示尿液中大部分TRH-LI是<EEP-NH2。在类癌肿瘤患者中,尿TRH-LI水平升高(1.35 - 962.4 ng/mL)。尿TRH-LI与尿肌酐呈正相关,且TRH-LI的尿清除率与肾小球滤过率相似。此外,17名血液透析患者的血清TRH-LI升高(43 - 373 pg/mL)。这表明血清<EEP-NH2通过肾小球滤过清除,肾小管重吸收很少。在11名前列腺癌男性患者中评估了前列腺作为尿TRH-LI来源的可能作用,结果显示前列腺切除术后尿TRH-LI排泄减少25%(0.19±0.02对0.15±0.01 ng/μmol肌酐,均值±标准误)。然而,16名单侧尿路梗阻患者的自然排尿尿液和通过肾造瘘管获取的尿液中的TRH-LI相似(0.15±0.01对0.14±0.01 ng/μmol肌酐)。这些数据表明:1)人血清中的TRH-LI主要代表<EEP-NH2,其通过肾脏排泄清除;2)尿中部分<EEP-NH2来源于前列腺分泌入血而非直接入尿;3)尿<EEP-NH2可作为类癌肿瘤的标志物。